Indomira is a U.S. phytopharmaceutical company dedicated to establishing new standards for CBD and Hemp. As a vertically-integrated operation, we are developing clinically-proven medicines that enhance everyday health, provide preventive strategies, and address modern conditions.
As prohibition gives way to changing sentiment, an unprecedented wave of research around the world is validating the efficacy of Hemp and Cannabis, both as a medical treatment and a wellness therapy. This research is providing hope, awareness, and solutions for managing conditions such as cancer, chronic pain, epilepsy, and multiple sclerosis.
Indomira’s contribution to the development of the scientific framework for safe and effective use, education for healthcare professionals, and the evolution of public awareness is at the heart of our mission. Through research, education, and knowledge-sharing, we’re inspiring new thinking and informed decisions about Cannabis and health.
We integrate principles from traditional and modern medicine, taking into account the whole human and the whole plant, while being firmly grounded in research, evidence, and clinical experience.
As a vertically-integrated company, we maintain uncompromising standards in our agricultural operations, our production processes, and our research methodologies.
As a direct result of our philosophy and our approach, we produce the highest-grade, standardized Cannabis and botanical medicines to support health and address specific conditions.
The Conversation around Cannabis is Evolving
We are shaping that evolution through innovative, physician-formulated therapies and science-based outreach and advocacy. Here’s where we are, where we’ve been, and where we’re going.
Laying the foundationWe established Indomira’s U.S. based farm, regulation-compliant lab, and state-of-the-art research facility in Southern Oregon’s Rogue Valley. Our formulation team began development of proprietary CBD products based on clinical experience with over 3,000 patients. And with the tighter collaboration between our U.S. and New Zealand partners, our local mindsets began to turn global.
Going to market
The change of government in New Zealand brought a new outlook on medical Cannabis, and a constructive dialogue that accelerated the development of our international team and infrastructure. In the U.S., we launched our first CBD brand — Green Earth Medicinals. Customer response to our oral and topical formulas has been overwhelmingly positive.
Working closely with New Zealand authorities, the establishment of our licensed facility, and clinical trials, builds on the success of our U.S. experience. We continue to draw on our clinical experience and patient outcomes to shape more relevant therapies according to the highest standards for safe, effective, medical Cannabis.
We plan to expand our product offerings in the United States, New Zealand and China, and continue our clinical trials for pain management, cancer, and other conditions. We aim to strengthen our efforts — and accelerate regulatory change — by partnering with research professionals who share our mission and vision.
A New Chapter
By the end of the decade we envision a regulatory tipping point that will provide relief to millions of people who can benefit from medical Cannabis. This is just the start of unlocking its healing potential, as research accelerates and we continue to develop wellness and condition-specific therapies.
Cannabis is Medicine
The clinical utility of Cannabis has a rich legacy of more than 3,000 years. Despite the misguided “war on drugs” initiated by the United States, there is a global reawakening to the healing potential of Cannabis that grows by the day. This movement is inspiring individuals, medical professionals, scientists, and policymakers to imagine new solutions for the role of Cannabis in medicine and society.
For All Of Us
Everyone has a right to safe, sustainable, and effective solutions that support their health and lifestyle. Clinical evidence overwhelmingly supports Cannabis as an effective treatment for medical conditions like epilepsy and chronic pain. It’s also become increasingly popular in wellness practices as a part of fitness and culinary plans.
For Healthcare Providers
Clinical thinking is part of Indomira’s DNA. We educate and partner with healthcare providers looking to better understand the endocannabinoid system and plant science — as well as condition-specific applications, routes of administration, dosages, and cultivars. We believe that as Cannabis science matures, a new era in empowered healthcare will emerge.
For Regulators and Policymakers
Science, safety, and effective governance must inform the decisions governments make about regulating plant-based medicines. We work with advocates and policymakers alike to create an open, clear, and compassionate dialogue among scientists, regulators, manufacturers, and the public.
Knowledge is Inspiration
There are more than 28,000 published papers and more than 100 research studies in process on medical Cannabis around the world. The emerging wealth of knowledge will provide invaluable insight for everyday health and medical conditions. We look forward to publishing our findings as they become available. In the meantime, we’re sharing references, studies, news, and information that have inspired us.
Frontiers in Pharmacology, April 28, 2018
Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
Journal of Pain Research, April 23, 2018
FDA Briefing Document, April 19, 2018
Journal of Neurosurgical Psychiatry, February 5, 2018
European Journal of Internal Medicine, January 14, 2018
National Academy of Sciences, 2017
Cannabis and Cannabinoid Research, 2016
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients
International Journal of Molecular Sciences, August 10, 2017
Birkhäuser Verlag, 2005
Advanced Cannabis Phytopharmaceuticals
© 2020 Indomira. All Rights Reserved.